Biogen Inc (BIIB): Growth Products Take the Earnings Wheel , Can LEQEMBI Momentum and Apellis Integration Drive a Durable Reacceleration Story?

Biogen’s first quarter reinforces a company transitioning from legacy MS dependence toward a more diversified growth-driven earnings model, with growth products now surpassing the remaining MS franchise in revenue contribution. Total revenue increased 2% year over year to $2.5 billion, while growth products rose 12% to $851 million, supported by continued momentum in LEQEMBI, SKYCLARYS, and high-dose SPINRAZA. Earnings leverage remained strong, with non-GAAP EPS increasing 18% despite elevated R&D and launch-related investments, highlighting disciplined expense management alongside pipeline expansion. LEQEMBI remains the central growth driver, with global sales rising 74% year over year and strong long-term patient persistence supporting durability beyond initial plaque clearance. The upcoming subcutaneous formulation approval could further simplify adoption and expand physician utilization. Rare disease momentum also continues building, as SKYCLARYS expands internationally and high-dose SPINRAZA demonstrates encouraging early conversion trends. Strategically, the pending Apellis acquisition broadens Biogen’s nephrology and ophthalmology exposure through EMPAVELI and SYFOVRE while reducing reliance on any single therapeutic area. Meanwhile, multiple late-stage catalysts across Alzheimer’s, lupus, nephrology, and rare disease create a dense pipeline cadence into 2027. While execution risk, competitive pressure, and clinical volatility remain important variables, Biogen’s improving product mix and expanding pipeline breadth increasingly support a more durable growth profile. Can LEQEMBI’s accelerating adoption and the successful integration of Apellis transform Biogen into a sustainably diversified growth company beyond its legacy MS era?